Psychedelics
Numinus Bioscience’s Completes First Ever Legal Harvest of Magic Mushrooms
Canada NewsWire VANCOUVER, BC, Oct. 22, 2020 Numinus Bioscience’s developments include harvesting its first flush of Psilocybe mushrooms at its Health Canada licensed facility. VANCOUVER, BC , Oct. 22, 2020 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, […]
3 Psychedelische Business Modelle (und was am besten für Investoren ist)
Die Psychedelikaindustrie hat das Interesse von Pharmaunternehmen geweckt, die nach sichereren und effektiveren Produkten suchen, um ungedeckte medizinische Bedürfnisse im Bereich der psychischen Gesundheit zu befriedigen. Während psychedelische Moleküle vielversprechend sind, verlangen die Pharmahersteller, dass die Moleküle durch wissenschaftliche Techniken verbessert werden, um bestimmte therapeutische Ziele zu erreichen und Toxizitäten zu reduzieren. Es gibt drei […]
How One Company Is Making Tryptamines & Cannabinoids Greener
Cannabinoids and tryptamines have the potential to treat a wide range of diseases, which has generated significant interest among pharmaceutical companies in accessing purified compounds. Unfortunately, these compounds are often created in agricultural or chemical synthesis processes that are time consuming, complex, expensive—and wasteful. CB Therapeutics aims to leverage its biosynthesis platform built on […]
Cybin Raises C$45 Million: The Largest Go Public Capital Raise in the Canadian Psychedelic Sector
The COMPASS Pathways Inc. (NASDAQ: CMPS) initial public offering on the NASDAQ has reinvigorated the psychedelics industry over the past couple of weeks. While COMPASS Pathways Inc. is certainly one of the largest companies in the space, there are a handful of other companies, with experienced management teams, that have raised a significant amount of […]
3 Psychedelic Business Models (and What’s Best for Investors)
The psychedelics industry has captured the interest of pharmaceutical companies seeking safer and more effective products to address unmet medical needs in mental health. While psychedelic molecules have shown promise, pharmaceutical manufacturers are likely to require that the molecules be improved through scientific engineering to meet specific therapeutic goals and reduce toxicities. There are three […]
Psyched Wellness Begins Trading on the CSE
Psyched Wellness Ltd. (CSE: PSYC) (OTC Pink: DCNPF) (formerly Duncan Park Holdings Corporation) (the “Company” or “Psyched“) a life sciences company focused on the production and distribution of artisanal functional mushrooms, is pleased to announce that it has received approval for the listing of the Company’s common shares on the Canadian Securities Exchange (the “CSE“). The […]
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
Expanding research and development of naturally-derived psilocybin for future FDA IND-enabling and clinical studies October 20, 2020 07:00 ET | Source: Revive Therapeutics Ltd. TORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs […]
October 19, 2020 11:30 AM Eastern Daylight Time TORONTO–(BUSINESS WIRE)–CLARMIN EXPLORATIONS INC. (TSXV: CX.V) and CYBIN CORP. (“CYBIN” or the “Company”), a life sciences company focused on psychedelic pharmaceutical therapies, announce the closing of a private placement offering by the Company (the “Offering) of an aggregate of 60,000,000 subscription receipts (the “Subscription Receipts”) at a […]
Heroic Hearts Project (“HHP”), an international nonprofit organization that connects military veterans struggling with mental trauma to psychedelic therapies, and Field Trip Health Ltd. (CSE: FTRP) (“Field Trip”), the global leader in the development and delivery of technology-enabled psychedelic therapies, today announced entry into a strategic relationship to increase access to, and awareness of, psychedelic […]
Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“ Pharmather ” or the “ Company ”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company has entered into an exclusive license agreement with the University of Arizona for the development and commercialization of […]
Havn Life Applies for License to Produce and Sell Psilocybin
Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has submitted an application to Health Canada to obtain a Controlled Drugs and Substances Dealer’s Licence (“Licence”) for Psilocybin […]
Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD
A peer-reviewed study published today in the research journal PLOS ONE demonstrates that MDMA-assisted psychotherapy is remarkably cost-effective when compared to currently available treatments for posttraumatic stress disorder (PTSD). It is estimated that a public healthcare payer or private insurer making MDMA-assisted psychotherapy available to 1,000 patients with PTSD would reduce general and mental health care costs by $103.2 million over […]
Numinus Appoints Multidisciplinary Global Leaders to Its General Advisory Council
Recognized and respected leaders from technology, pharmacology, and health have joined Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI) as members of the Company’s General Advisory Council. Drawing on experience across a broad range of specialities including psychedelic medicine, mental health advocacy, performance optimization, and digital healthcare, the multidisciplinary council will provide unique insight […]
VANCOUVER, British Columbia, Oct. 14, 2020 (GLOBE NEWSWIRE) — NeuroPharm, Inc. (“NeuroPharm”), a wholly-owned subsidiary of Mydecine Innovations Group, Inc., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) announced today it has engaged FreeMind Group LLC to assist NeuroPharm in securing non-dilutive funding opportunities globally. NeuroPharm™ is developing a unique and proprietary set of pharmaceutical and natural […]
MAGICMED PRESENTS AT GRAVITAS TECHNOLOGY AND DIVERSIFIED INVESTOR DAY
We are pleased to announce that MagicMed Industries will be participating in the Gravitas Technology and Diversified Investor Day taking place virtually this Thursday, October 15th, 2020. MagicMed is scheduled to present at 10:45AM EST on Thursday, October 15th, 2020. We look forward to communicating our progress, sharing our growth strategy and fielding investor questions. The Gravitas Technology and Diversified Investor Day will […]
Toronto, Ontario–(Newsfile Corp. – October 13, 2020) – PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“) is pleased to announce that its wholly-owned subsidiary Interrobang Ltd. (doing business as Super Smart) (“Super Smart“) has begun to work with Essential Good LLC (“Essential Good“) to develop its Slim Winkel brand and establish an […]
CB Therapeutics Targets Psychedelics & Cannabis Markets
There’s little question that the market for cannabinoids and psychedelics are poised to experience significant growth over the coming years. While the demand for cannabinoids, like cannabidiol (CBD), has already seen tremendous growth, psychedelics represent a blue-sky market due to the potential to treat a wide range of mental health disorders. Let’s take a look […]
Field Trip Health Commences Trading on the CSE
Field Trip Health Ltd. (formerly Newton Energy Corporation) (” Field Trip ” or the ” Company “) (CSE: FTRP), the global leader in the development and delivery of technology-enabled psychedelic therapies, is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (the “CSE”) under the symbol FTRP tomorrow, October 6, 2020 . To coincide with […]
Newscope Capital Announces Listing on the CSE
Newscope Capital Corporation (d/b/a Pharmather) (“Pharmather” or the “Company”) (CSE: PHRM), a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company’s common shares have been approved for listing on the Canadian Securities Exchange (the “CSE”) and the Company expects to begin trading on the […]
Field Trip Adds Acclaimed Physician, Dr. Andrew Weil, to Medical Advisory Board
Field Trip Health Ltd. (CSE: FTRP) (“Field Trip”), the global leader in the development and delivery of technology-enabled psychedelic therapies, today announced the addition of Andrew Weil , M.D., world-renowned leader and pioneer in the field of integrative medicine, to its medical advisory board. In this role, Dr. Weil will provide Field Trip with medical advice and […]
Mind Cure Welcomes Dr. Jason Wallach to Scientific Advisory Board
Mind Cure Health Inc. (CSE: MCUR) ( “Mind Cure” or the “Corporation” ) is pleased today to announce the addition of Dr. Jason Wallach to the company’s scientific advisory board. Highly regarded for his work in both drug development and pharmacological research, Dr. Wallach has a PhD in Pharmacology and Toxicology from University of the Sciences ( Philadelphia, PA ), where he currently teaches in the […]
Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the “Company” or “Havn Life”) is pleased to announce that Mr. Vic Neufeld has been appointed as the Chairman of the Board of Directors of the Company (the “Board”). Mr. Neufeld brings a wealth of knowledge and experience in the Natural Health Food industry, having served as the Chief Executive Officer […]
Tryp Therapeutics Announces Formation of Psilocybin Scientific Advisory Board
Tryp Therapeutics Inc. (“Tryp” or the “Company“), a pharmaceutical company developing therapeutics specifically targeting diseases with high unmet medical needs announced today the formation of a Scientific Advisory Board (“SAB“) for its Psilocybin For Neuropsychiatry (“PFN™“) program. The PFN™ SAB is a preeminent group of experts in neuropsychiatry research and clinical care specifically chosen to […]
MindMed Announces $25 Million Bought Deal Public Offering
NEW YORK, Oct. 9, 2020 /CNW/ – Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (“MindMed” or the “Company”), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (the “Lead Underwriter”) pursuant to which the Lead Underwriter has agreed, on behalf of a […]
Wie der Psybrary ™ die Entdeckung psychedelischer Medikamente revolutionieren könnte Teilen
Laut Data Bridge Market Research wird der Markt für Psychedelika in den nächsten acht Jahren voraussichtlich mit einer durchschnittlichen jährlichen Wachstumsrate von 16,3% wachsen und bis 2026 6,85 Mrd. USD erreichen. Mit der Perspektive, eine breite Palette von psychischen Störungen zu behandeln führen bereits mehrere Organisationen klinische Studien in diesem Bereich durch. Werfen wir einen […]
Who’s Who in Psychedelic Clinical Trials
The psychedelic drug market could reach $6.85 billion by 2027, according to Data Bridge Market Research, which translates to a blistering 16.3% compound annual growth rate. As psychedelic treatments enter clinical trials, investors may want to keep an eye on the companies behind them as potentially coming first-to-market with revolutionary drugs. Let’s take a […]
GreenStar Biosciences Announces Launch of Science Advisory Board
GreenStar’s Science Advisory Board will provide guidance and external review of our research and development activities Vancouver, British Columbia–(Newsfile Corp. – October 7, 2020) – GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) (“GreenStar” or the “Company“) is pleased to announce the formation and launch of its science advisory board (the “Science Advisory Board“) and […]
MindMed To Provide Funding for Psychedelic Medicine Research Training Program at NYU Langone Health and NYU Grossman School of Medicine See Official Release Here NEW YORK, Oct. 5, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF), the leading psychedelic medicine biotech company, on the heels of filing a NASDAQ uplisting application, today announced a funding commitment to found […]
Havn Life joins UK Psychedelics Working Group with Leading International Scientists
Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that it has joined the Drug Science Medical Psychedelics Working Group consortium. The working group was launched by Drug Science, the […]
Dr. Dan Engle Joins Mind Cure’s Advisory Board
Mind Cure Health Inc. (CSE: MCUR) (“Mind Cure” or the “Corporation”) is pleased today to announce the addition of Dr. Dan Engle to the company’s scientific advisory board. Dr. Dan Engle is a world-renowned physician in both psychiatry and neurology and sits at the forefront of psychedelic research and peak performance training. His current practice combines functional medicine with […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]
NanoSphere Health Sciences is a biotechnology company that has developed and is commercializing its patent-pending NanoSphere Delivery SystemTM, a ground breaking platform using nanotechnology for the delivery of biological agents such as cannabinoids, supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond.
Headquartered in Lakewood, Colo., STWC Holdings is a complete ecosystem of entities and services that support the burgeoning cannabis industry.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
